Is Imcivree FDA Approved?
DrugStatusIndex provides a clear, data-driven view of the regulatory status of medications, compounds, and related products. This page explains whether Imcivree is FDA approved and how it is commonly categorized.
Overview
Imcivree is the brand name for setmelanotide, a prescription medication used for chronic weight management in patients with certain rare genetic and hypothalamic obesity disorders affecting the MC4R pathway.
FDA Status Details
Imcivree is classified as FDA Approved. It was originally approved by the FDA in 2020 and has since received expanded approvals, including patients as young as 2 years old and a 2026 approval for acquired hypothalamic obesity. :contentReference[oaicite:0]{index=0}
Approved Use
Imcivree is approved to reduce excess body weight and maintain long-term weight reduction in patients with Bardet-Biedl syndrome (BBS), POMC, PCSK1, LEPR deficiency, and acquired hypothalamic obesity in qualifying adult and pediatric patients. :contentReference[oaicite:1]{index=1}
Prescription Status
Imcivree is a highly specialized FDA-approved prescription medication and should not be confused with general weight-loss drugs or compounded peptide therapies marketed for standard obesity treatment.
Search Another Drug or Compound
Use DrugStatusIndex to review public regulatory status information for medications, compounds, and related products.